Typewriter Therapeutics is a start-up company that focuses on the commercialization of mRNA-based gene therapies using a cutting-edge platform technology that enables the targeted insertion of therapeutic genes. Founded in February 2022, the company builds on the research of Professor Emeritus Haruhiko Fujiwara of the University of Tokyo on transposons. With research facilities in Tokyo and Cambridge, USA, Typewriter is committed to bringing Japan-originated technology to the global stage. The company aims to provide innovative gene therapies to patients suffering from severe genetic disorders.